Abstract
The challenge for government and policy makers is to develop a regulatory framework sufficiently stringent to ensure that only tests that are sufficiently robust and useful are offered to patients and refunded by health care payers. Direct-to-consumer genetic testing (DTC-GT) claims to have placed genomics directly into the hands of consumers by allowing patients to easily obtain information about their genetic makeup, sometimes without having to even see a doctor, genetic counselor, or pharmacist. The type of DTC genetic tests being offered to the public varies from testing for lifestyle factors, nutrigenomics, ancestry, rare diseases, and susceptibility for common chronic diseases and includes pharmacogenetic testing for drug responses. Pharmacogenomic research is a promising discipline that could have a substantially positive impact on pharmaceutical development and population health in the future. Like research in most other biomedical fields, it raises its share of ethical, legal, and social issues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
